PRODUCTS & SERVICES

Our capabilities place AAHI at the intersection of emerging sciences, medicine, and the business of biotech, enabling us to provide technologies, services, and insights that advance the state-of-the art for the entire biomedical community.

AAHI provides custom vaccine and immunotherapy solutions with next generation features and functionality, translating into unique products capable of addressing pressing global health needs.

AAHI is uniquely positioned to support development of products based on our immune-enhancing platforms from bench to clinic. Our partnerships with large pharmaceuticals enable collaborations to bring our products to market, providing accessibility around the world.

Learn more about AAHI’s adjuvant formulations by visiting the Adjuvant Catalogue

Learn more about AAHI’s RNA Vaccine delivery vehicle

AAHI PIPELINE

By Platform Technology

AAHI’S ADJUVANT TECHNOLOGY HAS BEEN CLINICALLY TESTED IN NEARLY 10,000 HUMAN VOLUNTEERS AND HAS AN OUTSTANDING SAFETY PROFILE.

ADJUVANT	Preclinical	GMP/Tox	Phase 1	Phase 2	Phase 3
Squalene Emulsion	SE
TLR 4 Agonists	GLA-SE
	GLA-AF/Alum
	SLA-SE
TLR/ 7/8 Agonists	3M-052-AF/Alum
	3M-052-SE
TLR 4 Agonists + Saponin	GLA-LSQ
	SLA-LSQ
Dual Agonist	GLA-3M-052-LS

RNA DELIVERY VEHICLE	Preclinical	GMP/Tox	Phase 1	Phase 2	Phase 3
Nanostructured Lipid Carrier	NLC

By Disease Indication

AAHI’s immune-enhancing platform technologies support vaccine development around the world.

INDICATION	Preclinical	Phase 1
COVID-19	Adjuvanted Protein Vaccine (4)
	RNA Vaccine
Tuberculosis	Adjuvanted Protein Vaccine (2)
	RNA Vaccine
HIV	Adjuvanted Protein Vaccine (9)
	RNA Vaccine
Flavivirus	RNA Vaccine	Bivalent (Zika, yellow fever)
Pandemic Influenza	RNA Vaccine	Spray-dried
	RNA Vaccine	Bivalent (H7N9, H5N1)
Malaria	Adjuvanted Protein Vaccine (5)
Hepatitis C	Adjuvanted Protein Vaccine
Neglected Tropical Diseases	Hookworm
	Schistosomiasis (2)
All Adjuvanted Protein Vaccines	Schistosomiasis
	Leprosy